All Other Markets 
Argentina 
Armenia 
Australia 
Austria 
Azerbaijan 
Bahrain 
Belarus 
Belgium 
Brunei 
Bulgaria 
China 
Colombia 
Costa Rica 
Croatia 
Denmark 
Egypt 
El Salvador 
Finland 
France 
Georgia 
Germany 
Hong Kong 
Hungary 
India 
Iraq 
Ireland 
Israel 
Italy 
Japan 
Jordan 
Kazakhstan 
Lebanon 
Malaysia 
Mexico 
Moldova 
Myanmar 
Netherlands 
New Zealand 
Norway 
Oman 
Panama 
Peru 
Poland 
Portugal 
Qatar 
Romania 
Russia 
Saudi Arabia 
Singapore 
South Africa 
Spain 
Sweden 
Switzerland 
Taiwan 
Thailand 
Turkey 
Ukraine 
United Arab Emirates 
United Kingdom 
Venezuela Our Platforms
To fulfill the promise of precision medicine and to facilitate a deeper understanding of the biology of cancer and other complex diseases, Caris Life Sciences® has developed a patented and proprietary biotargeting system. ADAPT Biotargeting System™ measures millions of molecular interactions within complex biological systems for drug target identification, therapeutic discovery and development, companion diagnostics, blood-based cancer screening, and biomarker identification.
Caris Life Sciences also pioneered the first molecular testing offering to help physicians make more informed treatment decisions. As the industry leader, our Comprehensive Genomic Profiling Plus (CGP+) approach assesses DNA, RNA and Proteins to reveal the molecular drivers of cancer that serves as a blueprint to enable the delivery of personalized medicine.
Identifying novel molecular targets for drug development and diagnostics
Learn More
Molecular testing to guide optimum treatment selection by physicians
Learn More
Caris Presents New Data at ASCO 2017
Be sure to check out the 11 accepted clinical studies, including an oral abstract presentation and two poster discussions, presented at this year's ASCO Annual Meeting. The studies were conducted in collaboration with industry-leading academic and clinical institutions using Caris Molecular Intelligence, the company’s CGP+ molecular testing service.
The Power of Immunotherapy
Immune checkpoint inhibitors are rapidly ushering in a new era of precision medicine. Comprehensive genomic and proteomic profiling with CMI can help oncologists identify patients more likely to respond to these novel drugs. Learn more about PD-L1, MSI and Tumor Mutational Burden testing.
Tumor Mutational Burden
Tumor Mutational Burden for Immunotherapy Response is an emerging, quantitative indicator for predicting response to novel immune checkpoint inhibitors across a wide spectrum of tumor types.
Physicians
When the next step in treatment is uncertain, Caris Life Sciences illuminates a clearer path to personalized treatment selection with our industry leading, patented and proprietary offering, Caris Molecular Intelligence. Also, learn how we are pioneering a new era in drug development and advanced diagnostics with our proprietary ADAPT Biotargeting System.
Enable Precision MedicinePatients
Although cancer treatments have significantly advanced over the years, current cancer care options are failing too many patients. It’s time to treat cancer smarter. An analysis of your cancer with Caris Molecular Intelligence may identify biomarkers that could lead towards a better understanding of what is causing your cancer to grow and inform personalized treatments to specifically target your cancer.
Visit Patients PageLatest News and Social Media Posts
As a leader in precision healthcare and informatics, Caris Life Sciences is continually exploring new technologies and partnering with other trailblazers in the field. We’re always excited to share our most recent accomplishments and discoveries.
Visit News PortalSocial Media Posts